source
- Supreme Court rules generic Vascepa copy does not infringe patents, boosting skinny-label pathwayThe U.S. Supreme Court issued a decision that Hikma Pharmaceuticals’ generic version of Amarin’s heart drug Vascepa does not infringe the brand’s patents. The ruling clarified that the generic make…
- Innovent Biologics reports Phase 3 success for stomach cancer ADC, now under priority review in ChinaInnovent Biologics announced that its antibody‑drug conjugate (ADC) candidate has met the primary endpoint in a Phase 3 trial for advanced stomach cancer. The positive outcome has placed the produ…